Palladium-catalyzed decarboxylative coupling of benzoic acid derivatives using hydrazone ligands
摘要:
Palladium-catalyzed decarboxylative coupling of benzoic acid derivatives with arylboroxins gave biaryls using a catalytic amount of Pd(TFA)(2)-hydrazone Id system with Ag2CO3 at 80 degrees C in good yields. We also found that decarboxylative coupling with aryl(trialkoxy)silanes gave biaryls using a Pd(TFA)(2)-hydrazone 1g system with AgF in good yields. 2014 Elsevier Ltd. All rights reserved.
Asymmetric addition of arylboronic acids to α,β-unsaturated sulfonyl compounds proceeded in the presence of a rhodium catalyst coordinated with a chiral diene ligand to give high yields of the addition products with high enantioselectivity (96->99.5% ee). The diene ligand was proved to be essential for the formation of the addition products, while the use of a bisphosphine ligand mainly gave the cine-substitution
importance. An attractive strategy is the arylation of imines with organoboronreagents. Chiral Rh complexes have reached a high level of productivity for this reaction type. In this article we describe that an electron rich PdII catalyst also performs well in the arylation of aldimines, comparable to the best Rh catalysts. The ferrocenyl palladacycle‐acetate catalyst allows for a broad substrate scope and
Asymmetric addition of arylboroxines to δ-aryl-α,β,γ,δ-unsaturated ketones proceeded in the presence of an iridium catalyst coordinated with a chiral diene ligand to give high yields of δ-diaryl ketones with very high enantioselectivity.
Provided is a compound represented by the formula (I):
wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
Provided is a compound represented by the formula (I):
wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.